References
- Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47. doi: 10.1111/j.1365-2516.2012.02909.x.
- Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19(5): 660–7. doi: 10.1111/hae.12169.
- NovoEight® Summary of Product Characteristics, April 2018. Available from https://www.ema.europa.eu/en/documents/product-information/novoeight-epar-product-information_en.pdf (accessed 27 April 2020).
- Pollard D, Khair K, Holland M. Switching factor products: nurses’ experience with NovoEight. J Haem Pract 2020; 7(1): 59–69. doi: 10.17225/jhp00156.
- Chaugule SS, Hay JW, Young G. Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence 2015; 9:1623–30. doi: 10.2147/PPA.S92985.
- Remor E. Predictors of treatment difficulties and satisfaction with haemophilia therapy in adult patients. Haemophilia 2011; 17(5): e901–5. doi: 10.1111/j.1365-2516.2011.02578.x.
- Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence 2014; 8: 1713–20. doi: 10.2147/PPA.S64709.
- Pollard D, Khair K, Percier C, Wong Y, Shoemark R. Evaluation of MixPro® among users and nurses. J Haem Pract 2017; 5(1): 12–23. doi: 10.17225/jhp00106.
- Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19(5): 698–705. doi: 10.1111/hae.12165.
- Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19(5): 691–7. doi: 10.1111/hae.12159.
- Lentz SR, Janic D, Kavakli K, et al. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. Haemophilia 2018; 24(6): e391–e394. doi: 10.1111/hae.13617.
- Brand-Staufer B, Dahl PW, Johansen SD, Nohr AM. Turoctocog alfa is stable during storage at 40°C and multiple sequences of temperature cycling. Presented at WFH 2018 World Congress, Glasgow, UK, 21 May 2018.
- Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Prefer Adherence 2018; 12: 431–41. doi: 10.2147/PPA.S151812.
- Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med 2017; 8: 67–73. doi: 10.2147/JBM.S103796.